The BLCAP Knockout HEK293T Polyclonal Cells product provides a pool of HEK293T cells edited via CRISPR/Cas9 to disrupt the BLCAP gene, generating a mixed population with loss-of-function mutations. As a polyclonal knockout model, it circumvents the limitations of single-cell cloning, offering a more representative genetic background for functional analyses. This product is specifically designed for studying the tumor suppressor roles of BLCAP in human cellular contexts.
The host HEK293T cell line originates from human embryonic kidney cells transformed with SV40 large T-antigen, conferring high proliferative capacity and exceptional transfectability. These features have made HEK293T a staple in molecular and cellular biology for protein expression, lentivirus production, and gene editing applications. The line’s established use and consistent growth characteristics ensure reproducibility in knockout experiments.
At the molecular level, BLCAP acts as a tumor suppressor that is regulated by p53 and DNA damage signals, serving as a key node in apoptotic and anti-proliferative pathways. Its downstream targets include cyclin D1, Bcl-2, Bax, and caspase-3, thereby controlling cell cycle progression and apoptosis execution. BLCAP interacts with p53 and MDM2, and its activities intersect with the PI3K/AKT and MAPK signaling cascades. Loss of BLCAP leads to unchecked cell division and resistance to programmed cell death, hallmarks of oncogenic transformation.
In the HEK293T background, disruption of BLCAP provides a relevant model for cancers such as bladder carcinoma, hepatocellular carcinoma, and gastric cancer, where BLCAP is often downregulated. The polyclonal knockout pool enables researchers to study the impact of BLCAP loss in a population that mirrors the heterogeneous nature of tumors, facilitating bulk assays like proliferation screens and pathway activation profiling. This system is particularly useful for exploring how BLCAP deficiency alters cell signaling dynamics in a controlled experimental setting.
Research applications of these BLCAP knockout cells span functional genomics, cancer biology, and drug discovery. They are suitable for high-throughput screening of compounds that modulate BLCAP-related pathways, validation of potential therapeutic targets, and detailed mechanistic studies using techniques such as western blotting, RT-qPCR, apoptosis assays, proliferation assays, co-immunoprecipitation, and reporter assays. By providing a ready-to-use knockout population, this product accelerates investigation into BLCAP’s role in tumor suppression. For technical support or custom services, please contact Ascent Research.
